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in CCR2 KO mice in parallel to ERK 1/2 activation. Therefore, we used glycyrrhizic acid (50 mg/kg), an
HMGB1 inhibitor in WT mice injected with LPS, and mortality was fully abolished. Thus, drugs targeting
CCR2 and HMGB1 could represent future resources for sepsis treatment.
 2013 Elsevier Inc. All rights reserved.Introduction
Sepsis is a systemic inﬂammatory syndrome that leads to lethal
damage to organs [1]. Sepsis is the second most prevalent cause of
non-cardiac mortality in intensive care units, with death rates
ranging from 20% to 50%, and the lung is the most frequent site
of infection, with 44% incidence [2]. The initial stimulus for sepsis
is an infection that generates a broad response within an organism,
generally an unregulated manner [3]. Signs of sepsis found in hu-
mans, such as fever and lethargy, can also be observed in rodents
by infection involving bacterial peritonitis, caecal perforation and
connection, among other models of pneumonia [4]. Gram-negative
bacteria are responsible for approximately 60% of sepsis cases [5].
In laboratory animals, lipopolysaccharide (LPS)2 from Escherichia
coli is frequently used as a model of sepsis [6,7]. LPS (also known
as endotoxin) is located on the outer membrane of Gram-negativebacteria and plays an important role in the release of proinﬂamma-
tory mediators, the activation of nuclear factors (such as NFkB and
AP-1) and the imbalance between oxidants and antioxidants [8,9].
Monocyte chemoattractant protein-1 (MCP-1) is a member of
the CC chemokine subfamily and a potent chemotactic factor for
monocytes [10]. The contribution of MCP-1 signalling through its
receptor CCR2 in monocyte adhesion to inﬂamed endothelium dur-
ing sepsis is not fully understood. Another protein not fully under-
stood in sepsis is a highly mobile protein (HMGB1) that is secreted
by macrophages, dendritic cells, and tumour endothelial cells and
released in the necrosis process and has been reported as a ‘‘late
proinﬂammatory mediator in sepsis’’, the secretion of which can
be detected from 8 to 32 h after endotoxaemia [11–13]. Patients
with sepsis have elevated serum levels of HMGB1, and these levels
are associated with increased mortality, suggesting that clinical
intervention by blocking or neutralising HMGB1 could be a viable
option [14–16]. HMGB1 can induce the activation of intracellular
signalling pathways through interactions with at least three path-
ways of recognising receptor patterns: activation of toll-like recep-
tor types 2 and 4 and receptor for advanced glycation end products
[17]. Thus, extracellular HMGB1 works synergistically with other
pro-inﬂammatory mediators to induce responses of innate immu-
nity [18–21].
In the present study, we investigated LPS-induced endotoxic
shock with respect to the MCP-1/CCR2 response by time and dose.
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cal, redox and inﬂammatory proﬁles.Material and methods
Reagents
The following reagents were purchased from Sigma Chemical
(St. Louis, MO, USA): acrylamide, bovine serum albumin, eosine,
glycyrrhizic acid, hematoxylin, hexadecyltrimethylammonium
bromide (HTAB), lipopolysaccharide from Escherichia coli strain
0111:B4, myeloperoxidase, naphthylenediamide dihydrochloride,
nitroblue tetrazolium, sodium acetate buffer, sodium chloride, so-
dium dodecylsulphate, sodium nitrite, sulphanilamide and
3,30,5,50-tetramethylbenzidine (TMB). Bradford assay reagents
were purchased from Bio-Rad (Hercules, CA, USA). Formalin,
hydrogen peroxide and phosphoric acid were purchased from Ve-
tec (Duque de Caxias, Rio de Janeiro, Brazil).
Animals
Male C57BL/6 (wild type; WT) and CCR2-deﬁcient mice (CCR2/
), 8–10 weeks old, were bred and maintained under standard con-
ditions in the animal facility of the Institute of Biomedical Science,
Federal University of Rio de Janeiro (Rio de Janeiro, Brazil). The
CCR2/ mice were generated by W.A. Kuziel [22] and were kindly
supplied. These CCR2/ mice were backcrossed with C57BL/6
mice for over 20 generations. All of the procedures were in accor-
dance with international guidelines (NIH) and Brazilian law (the
‘‘Arouca’’ Law) for the use of animals (Law 11,794 from 10/08/
2008), and this study received prior approval from the animal eth-
ics committee of the Federal University of Rio de Janeiro (IBCCF
108). During the experiment, the animals had controlled tempera-
ture and humidity (21 ± 2 C, 50 ± 10%, respectively) and were sub-
jected to 12 h light/dark cycles. During the experimental
procedures, the animals received standard chow and water ad
libitum.
Experimental design
To establish an optimal LPS concentration in mice, we per-
formed a dose–response study, using E. coli strain 0111:B4 to in-
duce endotoxic shock. LPS was suspended in saline, sonicated at
30 C for 15 min before use and inoculated i.p. at concentrations
of 20, 40 and 80 mg/kg in WT and KO animals (n = 10 each group).
The animals were monitored for 24 h after the inoculation of LPS,
and the mortality of each group was computed. The animals sub-
jected to endotoxaemia primarily developed signs of sepsis, such
as piloerection (suggesting hyperthermia), lethargy, and increased
respiratory and heart rates. At the end of the experimental design,
we established the optimal dose of 20 mg/kg of animal after
obtaining 70% survival of the mice, and subsequent analyses were
performed only in these mice. A second experimental design was
performed with C57BL/6 mice (n = 10 each group) and monitored
for 24 h. One hour after LPS inoculation (i.p.), these mice were trea-
ted with saline or 50 mg/kg glycyrrhizic acid (GA), an HMGB1
inhibitor. The groups were deﬁned as Control, GA, LPS and
LPS + GA. In order to study survival improvements by GA adminis-
tration, the following groups were analysed: LPS, LPS + GA, LPS KO
and LPS KO + GA.
Bronchoalveolar lavage
The lung air spaces were washed three times with buffered sal-
ine solution (500 lL) for a ﬁnal bronchoalveolar lavage (BAL) ﬂuidvolume of 1.2–1.5 mL. The collected BAL ﬂuid was stored on ice.
The total number of cells in the BAL ﬂuid was determined using
a Neubauer chamber. After BAL, the lungs were removed immedi-
ately, homogenised on ice with 10% (w/v) 0.1 M potassium phos-
phate buffer (pH 7.4) using a tissue homogeniser (Nova técnica
homogeniser model NT136, Campinas, São Paulo, Brazil), and cen-
trifuged at 800 g for 5 min. The supernatants were stored at 20 C
for biochemical analysis. The protein concentration in the lung
homogenate samples was determined by the Bradford method
[23].
ROS assay
We used a nitroblue tetrazolium assay to determine the reac-
tive oxygen species (ROS) production in the leukocytes from the
BAL by the method adapted from Choi and colleagues [24].
Myeloperoxidase (MPO) assay
MPO activity was measured using hydrogen peroxide, HTAB,
and TMB. Initially, 100 lL of each BAL sample was centrifuged with
900 lL of HTAB at 14,000 g for 15 min. The supernatant (75 lL)
was incubated with 5 lL of TMB for 5 min at 37 C. The mixture
was then incubated with 50 lL of hydrogen peroxide for 10 min
at 37 C, after which 125 lL of sodium acetate buffer was added.
The reaction was read using a microplate reader (Bio-Rad model
550, Hercules, CA, USA) at 630 nm [25]. The concentration of
MPO in the samples was determined using a standard curve estab-
lished using puriﬁed MPO.
Nitrite content
The nitrite levels in the lung homogenates were determined by
a method based on the Griess reaction [26]. A total of 100 lL of
sample was mixed with 100 lL of Griess reagent (1% sulphanila-
mide in 5% phosphoric acid and 0.1% naphthylenediamide dihydro-
chloride in water) and incubated at room temperature for 10 min.
The absorbance was measured with a plate reader at 550 nm. The
nitrite concentrations in the samples were determined from a stan-
dard curve generated using different concentrations of puriﬁed so-
dium nitrite.
Histopathology
Twenty-four hours after LPS administration, a separated group
of mice were killed, and after a midline thoracotomy, the trachea
was cannulated, and the lungs were ﬁxed by the instillation of
0.5 ml of buffered formalin (10%) at a pressure of 18–22 cmH2O
for 1–2 min. The trachea was then ligated, and the lungs, kidney
and liver were immersed in the ﬁxative solution for 48 h. The or-
gans were embedded in parafﬁn, sliced (5 lm) and stained with
H&E.
RNA extraction and quantitative real-time PCR
Lung tissue fragments were collected, snap frozen, and stored at
80 C in RNA later (Qiagen, Valencia, CA, USA). The total RNA was
isolated using the RNeasy tissue kit (Qiagen). Single-stranded
cDNA was synthesised using the High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA, USA) according to the manu-
facturer’s protocol. Quantitative real-time PCR was performed
using a 7300 real-time PCR System (Applied Biosystems), and the
threshold cycle numbers were determined using the RQ Study Soft-
ware (Applied Biosystems). The reactions were performed in trip-
licate, and the threshold cycle numbers were averaged. The 50 lL
reaction mixture was prepared as follows: 25 lL of Platinum SYBR
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gies, Alameda, CA, USA), 10 lmol/L of each primer (Table 1) and
10 lL of cDNA (100 ng). The reaction was cycled with a preliminary
uracil–DNA glycosylase treatment for 2 min at 50 C and a dena-
turation step for 2 min at 95 C, followed by 45 cycles of denatur-
ation at 95 C for 15 s, annealing for 15 s, and primer extension at
72 C for 15 s. This process was followed by melting point analysis
of the double-stranded amplicons, consisting of 40 cycles of 1 C
decrements (15 s each) beginning at 95 C. The ﬁrst derivative of
this plot, dF/dT, is the rate of change of ﬂuorescence in the reaction,
and a signiﬁcant change in ﬂuorescence accompanies the melting
curve of the double-stranded PCR products. A plot of dF/dT vs.
temperature displays these changes as distinct peaks. Thus, iNOS,
MCP-1, TNF-a, CCR2, TLR4, NRF2, and SIRT1 expression were
examined and normalised to a constitutive gene (b-actin and
HRTP-1), and the relative fold induction was calculated according
to the formula 2(DDCt) [27].Western blotting
Samples of lung homogenates and BAL were mixed with Lae-
mmle sample buffer and boiled for 5 min. Equal amounts of pro-
teins (50 lg/sample) were resolved by 8% sodium dodecyl
sulphate–polyacrylamide gel electrophoresis, and transferred onto
polyvinylidene ﬂuoride (PVDF) membranes (Bio-Rad, Hercules, CA,
USA). The membranes were probed with speciﬁc antibodies and
dilutions: HMGB1 (1:1,000), ERK 1/2 (1:1,000) and pERK 1/2
(1:1,000); b-actin (1:1,000) served as the endogenous control.
Detection was observed with HRP-conjugated goat anti-rabbit
IgG secondary antibody. The bands were visualised by enhanced
chemiluminescence (Amersham™ ECL™ Prime Western Blotting
Detection Reagent, Pittsburgh, PA, USA) and quantiﬁed using the
ImageJ free software. HMGB1 was detected in BAL, whereas ERK
1/2 and pERK 1/2 were detected in the lung homogenates. All of
the experiments were performed in triplicate.Elisa
Samples of BAL from mice injected with LPS or saline and trea-
ted with GA or saline were used for dosage of CCR2, HMGB1 andTable 1
The primers used in the quantitative real-time PCR.
Gene Primer Sequence (50 ? 30)
iNOS Sense CCGGAGAGGAGACTTCACAG
Antisense TCCACGATTTCCCAGAGAAC
MCP-1 Sense ATTCTCCACACCCTGTTTCG
Antisense GATTCCTGGAAGGTGGTCAA
TNF-a Sense TAGCCAGGAGGGAGAACAGA
Antisense TTTTCTGGAGGGAGATGTGG
CCR2 Sense ATTCTCCACACCCTGTTTCG
Antisense GATTCCTGGAAGGTGGTCAA
TLR4 Sense GCTTTCACCTCTGCCTTCAC
Antisense GCGATACAATTCCACCTGCT
NRF2 Sense TCTCCTCGCTGGAAAAAGAA
Antisense AATGTGCTGGCTGTGCTTTA
SIRT1 Sense TGGCAAAGGAGCAGATTAGT
Antisense CTGCCACAAGAACTAGAGGA
b-actin Sense GCTACAGCTTCACCACCACA
Antisense TCTCCAGGGAGGAAGAGGAT
HRPT-1 Sense GCTACAGCTTCACCACCACA
Antisense TCTCCAGGGAGGAAGAGGAT
iNOS, inducible isoform of nitric oxide synthase; MCP-1, monocyte chemotactic
protein-1; TNF-a, tumour necrosis factor alpha; CCR2, chemokine (C-C motif)
receptor 2; TLR4, toll-like receptor 4; NRF2, nuclear factor (erythroid-derived 2)-
like 2; SIRT1, sirtuin (silent mating type information regulation 2 homolog) 1;
HRPT-1, hypoxanthine phosphoribosyl-transferase 1.MCP-1 measured using ELISA kits (MyBioSource Inc., San Diego,
CA; Chondrex, Redmond, WA; R&D, Minneapolis, MN-USA).
Statistical Analyses
The data are presented as the means ± standard error of the
means and were analysed by the Student t test with Welch’s cor-
rection, with p < 0.05. The symbols show the values of signiﬁcanceFig. 1. Three doses of LPS i.p. were tested to assess mouse survival, 20 (a), 40 (b)
and 80 mg/kg (c). Although CCR2 KO mice died when treated with 40 and 80 mg/kg
of LPS, the WT mice died sooner. We chose to conduct our other analyses only in
mice injected with 20 mg/kg of LPS i.p. These experimental designs were repeated
three times. (n = 10 per group/time point).
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was used for statistical analysis (GraphPad Prism version 5.0, San
Diego, CA, USA).Results
LPS-induced lethality is reduced in CCR2 KO mice
We tested three doses of LPS i.p. to check CCR2 involvement in
mice survival, 20 mg/kg (Fig. 1a), 40 mg/kg (Fig. 1b) and 80 mg/kg
(Fig. 1c). Although CCR2 KO mice deaths were observed in groups
injected with 40 and 80 mg/kg of LPS, the WT mouse deaths began
sooner. We choose to perform our other analyses only in mice in-
jected with 20 mg/kg of LPS i.p.
LPS-induced inﬂammatory and redox markers are altered in CCR2 KO
mice
We observed increased leukocyte inﬂuxes in the BAL of both
WT mice (threefold, p < 0.001) and CCR2 KO mice (twofold,
p < 0.001) injected with LPS, compared with their respective con-
trol groups (Fig. 2a). The ROS in the BAL also increased in both
WT mice (almost 200%, p < 0.05) and CCR2 KO mice (150%,
p < 0.05) injected with LPS, compared with their respective controlFig. 2. Leukocytes and redox markers from lung and bronchoalveolar lavage or tissue o
Myeloperoxidase, and (d) Nitrite. The data were expressed as the means ± SEM. The stati
considering the signiﬁcance level to be 5%. ⁄p < 0.05 and ⁄⁄⁄p < 0.001 compared with the re
measured in lung homogenates. The other measurements were performed in the BAL. ngroups (Fig. 2b). The MPO in the BAL, an indirect method for neu-
trophil quantiﬁcation, was increased in both WT mice (p < 0.001)
and CCR2 KO mice (p < 0.001) injected with LPS, compared with
their respective control groups (Fig. 2c). Finally, the nitrite was
measured in lung homogenates, and we observed an increase in
WT mice (p < 0.05) injected with LPS compared with control group
(Fig. 2d). The nitrite levels in the CCR2 KO mice injected with LPS
were no different from those of the control group.LPS-induced endotoxic shock damaged lung, kidney and liver
Lung-related sepsis is common, but for a 24 h experimental de-
sign, it is not the cause of death. We look then for other organs,
such as the kidney and liver. We observed congestion, haemor-
rhage and leukocytes on the lung parenchyma in WT mice
(Fig. 3b) injected with LPS compared with the control group
(Fig. 3a). The lung histology of CCR2 KOmice (Fig. 3d) injected with
LPS was not different from that of the control group (Fig. 3c). The
kidneys of WT mice (Fig. 3f) injected with LPS showed that the re-
nal tubular cells underwent signiﬁcant vacuolar degenerative
changes and leukocyte inﬁltrations in the glomeruli and interstit-
ium compared with the control group (Fig. 3e). CCR2 mice injected
with LPS (Fig. 3h) showed lesser kidney leukocyte inﬁltrations and
no vacuolar degenerative changes compared with WT micef mice injected with LPS (20 mg/kg). (a) Total cells, (b) Reactive oxygen species, (c)
stical analyses were performed by unpaired Student T tests with Welch’s correction,
spective control group. # p < 0.05 and ## p < 0.01 compared with LPSWT. Nitrite was
= 10 per group.
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showed wide-range laminated necrosis, acidophilia changes, and
parenchyma leukocyte inﬁltrations compared with the control
group (Fig. 3i). Liver tissue from CCR2 mice injected with LPS
(Fig. 3l) showed only lesser parenchyma leukocyte inﬁltrations
compared with the control group (Fig. 3k).
LPS-induced expression of inﬂammatory and redox markers is altered
in CCR2 KO mice
We observed an increase in iNOS mRNA in the LPS-injected
groups WT (p < 0.05) and CCR2 KO (p < 0.05) compared with con-
trols (Fig. 4a). The mRNA of MCP-1 was also increased in the WT
mice (p < 0.05) compared with the control group. However, MCP-
1 mRNA was reduced in CCR2 KO mice (Fig. 4b) injected with LPS
compared with the control group (p < 0.01). The expression of
TNF-a was increased in both LPS-injected groups, WT (p < 0.01)
and CCR2 KO (p < 0.05), compared with controls (Fig. 4c). CCR2
expression was observed only in WT mice, and those injected with
LPS showed an increase in the mRNA (p < 0.001) compared with the
control group (Fig. 4d). Toll 4 receptor expression was also in-
creased in both LPS-injected groups, WT and CCR2 KO (p < 0.05
for both), comparedwith controls (Fig. 4e). The expression of the re-
dox markers NRF2 (Fig. 4f) and SIRT1 (Fig. 4g) was reduced in LPS-
injected mice, both WT (p < 0.05) and CCR2 (p < 0.05), compared
with controls. The reduction in SIRT1 was less pronounced in
CCR2 (p < 0.05) than in WT mice (p < 0.01).
LPS-induced endotoxic shock via ERK and HMGB1
We observed an increase in HMGB1 expression in the BAL from
WT mice (p < 0.001) injected with LPS in comparison with the con-
trol group, whereas CCR2 KO mice injected with LPS were similar
to their respective control group (Fig. 5). At the same time point,a b 
e f 
i j 
Fig. 3. Photomicrographs of lung (a–d), kidney (e-h) and liver (i–l). We observed conges
with LPS compared with the control group (a). The lung histology of CCR2 KO mice (d) inj
of WT mice (f) injected with LPS showed that renal tubular cells underwent signiﬁcan
interstitium compared with the control group (e). CCR2 mice injected with LPS (h) sh
compared with WT mice (g). The liver tissue of WT mice (j) injected with LPS showe
inﬁltrations compared with the control group (i). Liver tissue from CCR2 mice injected w
with control group (k). 400, H&E. (n = 5 per group).we observed an increase in pERK 1/2 parallel to a reduction in
ERK 1/2 in WT mice injected with LPS (Fig. 5). The pERK 1/2: ERK
1/2 ratio in CCR2 KO mice injected with LPS was similar to that
of the respective control group (Fig. 5).
HMGB1 inhibition blocked mouse mortality after LPS-induced
endotoxic shock
Until now, we observed that CCR2 is critical for mouse survival
after LPS. It appears that HMGB1 signalling was altered by CCR2
KO via the ERK 1/2 pathway. Therefore, we used glycyrrhizic acid
(GA), an HMGB1 inhibitor, as a target to reduce the impact of endo-
toxic shock caused by LPS. We observed that 100% of LPS + GA mice
were alive at 24 h of experimental design, whereas 30% of the LPS
micewere dead (Fig. 6). CCR2 KOmice subjected to endotoxic shock
were 90% protected from death, whereas the survival rate of CCR2
KO + GA group reached 100% (Fig. 6).We also observed reduced leu-
kocyte inﬂuxes (Fig. 7a) and HMGB1 (Fig. 7b) levels in the BAL from
LPS + GA mice compared with the LPS group (p < 0.001). ROS
(Fig. 7c) and MCP-1 (Fig. 7d) were increased in the LPS group
(p < 0.01 and p < 0.05) compared with the GA group. The ROS and
MCP-1 of the LPS + GA group were not different from those of the
GA group. CCR2 levels in the tissue from LPS mice were increased
(p < 0.05) compared with control group (Fig. 7e). GA did not reduce
CCR2 levels in LPS injected mice. Histological analyses of the lung,
kidney and liver of LPS + GAmice (Fig. 8a–c) showed reduced leuko-
cyte inﬁltration and tissue damage relative to the LPSmice (Fig. 3b, f
and j). No differenceswere observed between the control group and
the GA group for any of the analyses performed.Discussion
In thepresent study,wedemonstrated that the chemokine recep-
tor CCR2 is important in the inﬂammatory events of experimentalc d 
g h 
l m
tion, haemorrhage and leukocytes on the lung parenchyma in WT mice (b) injected
ected with LPS was not different from that of the control group (c). The kidney tissue
t vacuolar degenerative changes and leukocyte inﬁltrations in the glomeruli and
owed lesser kidney leukocyte inﬁltrations and no vacuolar degenerative changes
d wide-range laminated necrosis, acidophilia changes, and parenchyma leukocyte
ith LPS (l) showed only lesser parenchyma leukocyte inﬁltrations when compared
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to themortality observed during the ﬁrst 24 h of endotoxic shock. At
this point, CCR2 andHMGB1 could present important targets for the
treatment of sepsis in its initial stages.
Sepsis is deﬁned as a systemic inﬂammatory response to infec-
tion characterised by the deregulated production of proinﬂamma-
tory cytokines [1]. Clinical trials have demonstrated that
neutrophils in patients with sepsis express high levels of CCR2,
and disease severity (SOFA scores and APACHE) correlated posi-
tively with the observed increase in neutrophil chemotaxis to
MCP-1. These authors also conclude that inhibition of CCR2 signal-
ling may be beneﬁcial in patients with sepsis and multiple organ
failure [28]. To test this hypothesis, we initially observed the sur-
vival dose–response curve in CCR2 knockout mice compared with
wild type subjected to endotoxaemia, and we observed that there
was greater mortality in the wild type mice. Maus and co-workers
also demonstrated that the intratracheal administration of LPSFig. 4. The expression of inﬂammatory and redox markers in the lung homogenates of m
monocyte chemotactic protein-1, (c) tumour necrosis factor alpha, (d) chemokine (C-C m
and (g) sirtuin (silent mating type information regulation 2 homolog) 1. All of the anal
phosphoribosyl-transferase 1). The data were expressed as the means ± SEM. The statisti
considering the signiﬁcance level to be 5%. ⁄p < 0.05, ⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001 comparecauses an inﬂammatory response of the ampliﬁer CCR2 chemokine
receptor after stimulation [29].
We used LPS as a promoter of endotoxaemia, which is responsi-
ble for the release of certain inﬂammatory cytokines, such as TNF-
a, which is produced by monocytes/macrophages, T lymphocytes,
natural killer cells and mast cells [3,8]. These cells induce increased
expression of adhesion molecules in endothelial cells, expression
and secretion of chemokines by macrophages, and expression of
enzymes, such as cyclooxygenase-2 (COX-2) and NO-synthase
(iNOS) [30–32]. TNF-a plays an important role in this complex
pathophysiological response by stimulating leukocytes and endo-
thelial cells to release other cytokines to express adhesion mole-
cules on the cell surface and increase the turnover of arachidonic
acid [33]. Therefore, we suggest that the increased expression of
TNF-a may have been responsible for iNOS producing NO from L-
arginine and for the metabolism of this NO to nitrite and nitrate.
This response involving NO overproduction led to hypotensionice injected with LPS (20 mg/kg). (a) inducible isoform of nitric oxide synthase, (b)
otif) receptor 2, (e) toll-like receptor 4, (f) nuclear factor (erythroid-derived 2)-like 2,
yses were normalised to a constitutively expressed gene (b-actin or hypoxanthine
cal analyses were performed by unpaired Student’s T tests with Welch’s correction,
d with the respective control group. n = 5 per group.
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ity observed in the WT animals. The ﬁnding that the CCR2 knock-
out mice showed lower levels of nitrite suggests a logical
hypothesis regarding the role of NO metabolism in endotoxic
shock-induced lethality. Interestingly, studies on septic patients
and in septic mice have also demonstrated increased levels of ni-
trite and nitrate [34,35]. Moreover, Mitaka and co-workers showed
that the levels of nitrite/nitrate in the plasma of septic patients are
correlated with the severity of the syndrome and multiple organ
dysfunctions, measured by APACHE II and SOFA scores, respec-
tively [36].
The accumulation of neutrophils has been reported in the
development of pulmonary sepsis, not only favouring bacterial
translocation but also promoting the production of ROS [37]. Our
study revealed elevated ROS and MPO in both WT mice and
CCR2 KO mice. However, the CCR2 KO mice exhibited a less pro-
nounced elevation of ROS and MPO than the WT mice, thus sug-
gesting a degree of regulation of the oxidants produced by
neutrophils through CCR2. In this context, the receptors involved
in the mechanism of sepsis induced by LPS are the Toll-like recep-
tors (TLRs) which mediate ‘‘scavenger’’ responses. Toll-like recep-
tor 4 (TLR4), the receptor with the greatest importance in theFig. 5. Western blotting of HMGB1, ERK 1/2 and p-ERK 1/2. There is an increase in
HMGB1 expression in the BAL of WT mice injected with LPS in comparison with the
control group, whereas CCR2 KO mice injected with LPS were similar to the
respective control group. At the same time point, we observed an increase in pERK
1/2 that paralleled a reduction in ERK 1/2 in WTmice injected with LPS. The pERK 1/
2: ERK 1/2 ratio in CCR2 KO mice injected with LPS was similar to that of the
respective control group. WB was repeated three times.induction of sepsis by LPS, acts as a signalling centre for transcrip-
tion factors for inﬂammation and redox responses [38].
In our study, increased expression of TLR4 detected in the two
groups and thus can conﬁrm the host response to the LPS stimulus.
In sepsis, there are a variety of secreted chemokines, such as MCP-
1, a protein that exerts an attraction for monocytes and macro-
phages by interacting with its surface receptor, CCR2 [22,28,29].
Several studies have shown that the levels of MCP-1 are increased
in animal models of sepsis [10,39]. In our study, we have found a
decrease in the expression of this chemokine in CCR2 KO mice,
and we suggest that this decrease is due to a negative feedback
mechanism in which the absence of CCR2 reduces MCP-1 and, con-
sequently, mortality.
NFR2 is a transcription factor that is essential for the regulation
of antioxidant enzymes. Mice deﬁcient in NFR2 are sensitive to oxi-
dative stress and inﬂammatory insults [40–44]. In our study, the
expression of NRF2 was decreased in both groups exposed to
endotoxaemia, and thus, we assume that the period of 24 h used
for the endotoxaemia was insufﬁcient to analyse the expression
of NRF2.
Previous studies have reported that decreased activity of SIRT1
enhances the NFjB signaling and enhances inﬂammatory re-
sponses [45,46]. Also, the overexpression of SIRT1 have been
shown to disturb cellular redox balance by repressing the NRF2-in-
duced antioxidant defense [47]. These data indicate a crosstalk
with NFjB system, suggesting that SIRT1 can not only repress
the ROS production but also reduce the antioxidant defense. Inter-
estingly, although both SIRT-1 and NRF2 expressions were de-
creased in mouse groups exposed to LPS, CCR2 KO mice showed
lower inﬂammatory responses and lower ROS production when
compared to WT mice.
We evaluated the role of CCR2 in the expression of HMGB1 as a
major target in experimental sepsis. This DNA linker nuclear pro-
tein, present in both the nucleus and the cytoplasm or in the cyto-
plasmic membrane, is secreted by monocytes/macrophages and
neutrophils after stimulation with LPS, IL-1 and TNF- a
[18,20,48]. Several studies have demonstrated a central role of
HMGB1 in organ dysfunction associated with severe sepsis. In pa-
tients with severe sepsis, as well as animals subjected to experi-
mental models of sepsis, systemic levels of HMGB1 were
elevated [49–54]. Nevertheless, neutralisation of this cytokine with
antibodies protected the animals from lethal endotoxaemia and
sepsis induced by the CLP model [55,56].Fig. 6. Mouse survival after LPS-induced endotoxic shock. We observed that 100%
of the LPS + GA and LPS KO + GA mice were alive 24 h into the experiment, whereas
10% of the mice in the LPS KO group and 30% of the mice in the LPS group were
dead. GA-glycyrrhizic acid (50 mg/kg). These experimental designs were repeated
two times. (n = 5 per group/time point).
Fig. 7. Leukocytes, redox and proinﬂammatory markers from bronchoalveolar lavage of mice injected with LPS and treated with glycyrrhizic acid. (a) Total cells, (b) high
mobility group box 1 protein, (c) reactive oxygen species, (d) monocyte chemotactic protein 1, and (e) chemokine (C-C motif) receptor 2. GA-glycyrrhizic acid (50 mg/kg). The
data were expressed as the means ± SEM. The statistical analyses were performed by unpaired Student’s T tests with Welch’s correction, considering the signiﬁcance level to
be 5%. ⁄p < 0.05 and ⁄⁄⁄p < 0.001 compared with the control group. ### p < 0.001 when compared with the LPS group. n = 6 per group.
a b c 
Fig. 8. Histological analyses of the lung, kidney and liver of LPS + GA mice (a, b and c) showed less leukocyte inﬁltration and tissue damage than was observed in LPS mice
(Fig. 2b, f and j). GA-glycyrrhizic acid (50 mg/kg). 400, H&E.
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protein has two isoforms (ERK 1 and ERK 2), which are activated
in the cascade of mitogen-activated protein kinase in response to
endotoxin and oxidative stress, among other stimuli, and may be
involved primarily in cell differentiation and proliferation [57].
The stimulation of macrophages in culture with MCP-1 rapidly in-
duces the activation of ERK signalling as a promoter of the inﬂam-
matory response [58]. In addition, Lee and co-workers found that
the activation of ERK has an important role in lung injury induced
by LPS; therefore, their inhibition was signiﬁcantly effective in
reducing the cascade catalyst by reducing the leakage of protein
and neutrophil inﬂuxes [6]. Thus, we suggest that, in our study,
WT mice injected with LPS were more susceptible to the systemic
effects of endotoxic shock and this effect was synergistic with the
secretion of HMGB1.
We are the ﬁrst group to demonstrate the importance of MCP-1/
CCR2 in HMGB1 expression. Additionally, we conﬁrmed the inhibi-
tion of HMGB1 expression by glycyrrhizic acid (GA), offering 100%
protection against LPS-induced lethality in mice, and this ﬁnal
point suggests a critical role for HMGB1 in this model of endotoxic
shock that mimics sepsis in humans. GA was the subject of several
studies regarding its inﬂammatory context [59–61]. GA inhibits themanifestation of anti-inﬂammatory responses that appear in asso-
ciation with systemic inﬂammatory response syndrome (SIRS)-like
reactions [62]. We observed a reduction in the number of leuko-
cytes in the mice injected with LPS and treated with GA, as well
as reductions in HMGB1, ROS and MCP-1. Moreover, the histology
of the lung, kidney and liver from these mice were similar to that of
the control group. These facts help us to suggest a critical role for
HMGB1 as a systemic marker of endotoxic shock induced by LPS
in mice.
Glycyrrhizic acid is a known functional inhibitor of extracellular
HMGB1 which has been reported to show anti-inﬂammatory prop-
erties [63]. Glycyrrhizic acid treatment has been shown to decrease
both inﬂammation and infection in CLP-induced liver damage by
regulating polymorphonuclear (PMN) chemoattraction, suggesting
that it is likely that HMGB1 exerts its chemotactic function toward
PMNs extracellularly [64]. The present study may shed some light
in this matter as we are the ﬁrst group to indentify the association
between CCR2 and HMGB1, as key LPS-induced pulmonary sepsis
parameters were signiﬁcantly reduced in mice treated with glyc-
yrrhizic acid. Recently, the association between HMGB1 inhibition
in macrophages has been shown to reduce the release of important
inﬂammatory markers, such as prostaglandin E2 and TNF-a [65],
80 J.N. Alves et al. / Archives of Biochemistry and Biophysics 537 (2013) 72–81two key cytokines that are involved in LPS susceptibility and fur-
ther increase of mouse in life [66]. In addition, HMGB1 inhibition
has been shown to block cytokine expression via JNK/NFjB path-
way which led the authors to suggest HMGB-1 could act as a ther-
apeutic target for inﬂammation, which is in accordance with the
present study [67].
The lack of on information regarding to the levels of ERK signals
in treatment of glycyrrhizic acid represents a limitation of the pres-
ent study. However, it is most likely that ERK signaling may also be
reduced, as mouse life-span improvement shown in the present
study, has been repeatedly shown to depend on ERK1/2 cascade
inhibition and mice lacking the MKP-2 gene had a survival advan-
tage over wild-type mice when challenged with LPS [68–70].
These facts help us to suggest a critical role for HMGB1 as a sys-
temic marker of endotoxic shock induced by LPS in miceConclusions
In conclusion, we demonstrated that, after stimulation with LPS,
CCR2 KO mice survive more frequently and exhibit altered inﬂam-
matory and redox proﬁles. These parameters were accompanied by
the ERK 1/2 pathway and offered us the opportunity to investigate
HMGB1 involvement in WT mice using an inhibitor. Three lessons
can be highlighted from our study: (1) CCR2 and HMGB1 play crit-
ical roles in our endotoxic shock model, (2) the participation of
chemokines related to monocytes/macrophages are as important
as neutrophil responses for sepsis in mice, and (3) redox participa-
tion in CCR2 KO mice is quite limited, considering the inﬂamma-
tory events. Thus, drugs that target CCR2 and HMGB1 could
represent future resources for sepsis treatment in humans, partic-
ularly in the early stages of this condition.Acknowledgments
The authors are grateful to the Brazilian research agencies FA-
PERJ, FAPESP, CAPES and CNPq for grants (to professors) and schol-
arships (to undergraduate and graduate students). We are grateful
also to all undergraduate students from LABCOM for technical ad-
vices with biochemical analyses.References
[1] D.G. Remick, P.A. Ward, Shock 24 (Suppl. 1) (2005) 7–11.
[2] M. Moss, Clin. Infect. Dis. 41 (Suppl. 7) (2005) S490–S497.
[3] H.M. Razavi, L. Wang, S. Weicker, G.J. Quinlan, S. Mumby, D.G. McCormack, S.
Mehta, Crit. Care Med. 33 (2005) 1333–1339.
[4] L.F. Poli-de-Figueiredo, A.G. Garrido, N. Nakagawa, P. Sannomiya, Shock 30
(Suppl. 1) (2008) 53–59.
[5] S. Leekha, H.C. Standiford, Crit. Care Med. 39 (2011) 1995–1996.
[6] C. Lee, H.J. An, J.L. Kim, H. Lee, S.G. Paik, Mol. Cells 27 (2009) 251–255.
[7] K. Tsoyi, T.Y. Lee, Y.S. Lee, H.J. Kim, H.G. Seo, J.H. Lee, K.C. Chang, Mol.
Pharmacol. 76 (2009) 173–182.
[8] V.M. Victor, M. Rocha, M. De la Fuente, Int. Immunopharmacol. 4 (2004) 327–
347.
[9] V.M. Victor, M. Rocha, J.V. Esplugues, M. De la Fuente, Curr. Pharm. Des. 11
(2005) 3141–3158.
[10] R.D. Ramnath, S.W. Ng, A. Guglielmotti, M. Bhatia, Int. Immunopharmacol. 8
(2008) 810–818.
[11] A.B. Reddy, S.K. Srivastava, K.V. Ramana, Cytokine 48 (2009) 170–176.
[12] D. Tang, R. Kang, W. Xiao, H. Zhang, M.T. Lotze, H. Wang, X. Xiao, Am. J. Respir.
Cell Mol. Biol. 41 (2009) 651–660.
[13] M.A. van Zoelen, H. Yang, S. Florquin, J.C. Meijers, S. Akira, B. Arnold, P.P.
Nawroth, A. Bierhaus, K.J. Tracey, T. van der Poll, Shock 31 (2009) 280–284.
[14] L.Y. Gamez-Diaz, L.E. Enriquez, J.D. Matute, S. Velasquez, I.D. Gomez, F. Toro, S.
Ospina, V. Bedoya, C.M. Arango, M.L. Valencia, G. De La Rosa, C.I. Gomez, A.
Garcia, P.J. Patino, F.A. Jaimes, Acad. Emerg. Med. 18 (2011) 807–815.
[15] A. Bitto, M. Barone, A. David, F. Polito, D. Familiari, F. Monaco, M. Giardina, T.
David, R. Messina, A. Noto, V. Di Stefano, D. Altavilla, A. Bonaiuto, L. Minutoli, S.
Guarini, A. Ottani, F. Squadrito, F.S. Venuti, Pharmacol. Res. 61 (2010) 116–120.
[16] T. Hatada, H. Wada, T. Nobori, K. Okabayashi, K. Maruyama, Y. Abe, S. Uemoto,
S. Yamada, I. Maruyama, Thromb. Haemost. 94 (2005) 975–979.[17] C. Bopp, A. Bierhaus, S. Hofer, A. Bouchon, P.P. Nawroth, E. Martin, M.A.
Weigand, Crit. Care 12 (2008) 201.
[18] G. Chen, M.F. Ward, A.E. Sama, H. Wang, J. Interferon Cytokine Res. 24 (2004)
329–333.
[19] S. Dai, C. Sodhi, S. Cetin, W. Richardson, M. Branca, M.D. Neal, T. Prindle, C. Ma,
R.A. Shapiro, B. Li, J.H. Wang, D.J. Hackam, J, Biol. Chem. 285 (2010) 4995–
5002.
[20] N.K. Sun, C.C. Chao, Chang Gung Med. J. 28 (2005) 673–682.
[21] H. Wang, H. Yang, K.J. Tracey, J. Intern. Med. 255 (2004) 320–331.
[22] W.A. Kuziel, S.J. Morgan, T.C. Dawson, S. Grifﬁn, O. Smithies, K. Ley, N. Maeda,
Proc. Natl. Acad. Sci. USA 94 (1997) 12053–12058.
[23] M.M. Bradford, Anal. Biochem. 72 (1976) 248–254.
[24] H.S. Choi, J.W. Kim, Y.N. Cha, C. Kim, J. Immunoassay Immunochem. 27 (2006)
31–44.
[25] K. Suzuki, H. Ota, S. Sasagawa, T. Sakatani, T. Fujikura, Anal. Biochem. 132
(1983) 345–352.
[26] L.C. Green, D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, S.R.
Tannenbaum, Anal. Biochem. 126 (1982) 131–138.
[27] K.J. Livak, T.D. Schmittgen, Methods (San Diego Calif) 25 (2001) 402–408.
[28] A. Kapoor, C. Thiemermann, Am. J. Respir. Crit. Care Med. 183 (2011) 150–151.
[29] U.A. Maus, S. Wellmann, C. Hampl, W.A. Kuziel, M. Srivastava, M. Mack, M.B.
Everhart, T.S. Blackwell, J.W. Christman, D. Schlondorff, R.M. Bohle, W. Seeger,
J. Lohmeyer, Am. J. Physiol. Lung Cell. Mol. Physiol. 288 (2005) L350–L358.
[30] T. Uto, N. Suangkaew, O. Morinaga, H. Kariyazono, S. Oiso, Y. Shoyama, Am. J.
Chin. Med. 38 (2010) 985–994.
[31] P. Pratheeshkumar, G. Kuttan, Immunopharmacol. Immunotoxicol. 33 (2011)
73–83.
[32] H.S. Chae, O.H. Kang, Y.S. Lee, J.G. Choi, Y.C. Oh, H.J. Jang, M.S. Kim, J.H. Kim, S.I.
Jeong, D.Y. Kwon, Am. J. Chin. Med. 37 (2009) 181–194.
[33] Y. Tanaka, A. Otsuji, F. Amano, Biol. Pharm. Bull. 22 (1999) 1052–1057.
[34] J.P. Cobb, R.L. Danner, JAMA 275 (1996) 1192–1196.
[35] D. Le Roy, D. Heumann, M.P. Glauser, J. Mauel, J. Smith, S. Betz Corradin, Shock
10 (1998) 37–42.
[36] C. Mitaka, Y. Hirata, K. Yokoyama, H. Wakimoto, M. Hirokawa, T. Nosaka, T.
Imai, Shock 19 (2003) 305–309.
[37] Y. Wang, C. Bai, X. Wang, Expert Rev. Respir. Med. 2 (2008) 297–299.
[38] E.F. Kenny, L.A. O’Neill, Cytokine 43 (2008) 342–349.
[39] R.N. Gomes, R.T. Figueiredo, F.A. Bozza, P. Pacheco, R.T. Amancio, A.P.
Laranjeira, H.C. Castro-Faria-Neto, P.T. Bozza, M.T. Bozza, Shock 26 (2006)
457–463.
[40] J.Y. Choi, M.J. Kwun, K.H. Kim, J.H. Lyu, C.W. Han, H.S. Jeong, K.T. Ha, H.J. Jung,
B.J. Lee, R.T. Sadikot, J.W. Christman, S.K. Jung, M. Joo, Evid Based Complement
Alternat. Med. 2012 (2012) 974713.
[41] F. Khodagholi, S.K. Tusi, Mol. Cell. Biochem. 354 (2011) 97–112.
[42] K. Koh, J. Kim, Y.J. Jang, K. Yoon, Y. Cha, H.J. Lee, J. Neuroimmunol. 233 (2011)
160–167.
[43] H. Wang, T.O. Khor, C.L. Saw, W. Lin, T. Wu, Y. Huang, A.N. Kong, Mol. Pharm. 7
(2010) 2185–2193.
[44] R.K. Thimmulappa, C. Scollick, K. Traore, M. Yates, M.A. Trush, K.T. Liby, M.B.
Sporn, M. Yamamoto, T.W. Kensler, S. Biswal, Biochem. Biophys. Res. Commun.
351 (2006) 883–889.
[45] F. Yeung, J.E. Hoberg, C.S. Ramsey, M.D. Keller, D.R. Jones, R.A. Frye, M.W. Mayo,
EMBO J. 23 (2004) 2369–2380.
[46] A. Salminen, J.M. Hyttinen, K. Kaarniranta, J. Mol. Med. (Berl) 89 (2011) 667–
676.
[47] Y. Kawai, L. Garduno, M. Theodore, J. Yang, I.J. Arinze, J. Biol. Chem. 286 (2010)
7629–7640.
[48] H. Wang, O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, A.
Frazier, H. Yang, S. Ivanova, L. Borovikova, K.R. Manogue, E. Faist, E. Abraham, J.
Andersson, U. Andersson, P.E. Molina, N.N. Abumrad, A. Sama, K.J. Tracey,
Science 285 (1999) 248–251.
[49] W. Huang, Y. Tang, L. Li, Cytokine 51 (2010) 119–126.
[50] H. Wang, M.F. Ward, A.E. Sama, Shock 32 (2009) 348–357.
[51] H. Wang, S. Zhu, R. Zhou, W. Li, A.E. Sama, Expert Rev. Mol. Med. 10 (2008) e32.
[52] S. Karlsson, V. Pettila, J. Tenhunen, R. Laru-Sompa, M. Hynninen, E. Ruokonen,
Intensive Care Med. 34 (2008) 1046–1053.
[53] G.W. Waterer, Crit Care Med 35 (2007) 1205–1206.
[54] S. Qin, H. Wang, R. Yuan, H. Li, M. Ochani, K. Ochani, M. Rosas-Ballina, C.J.
Czura, J.M. Huston, E. Miller, X. Lin, B. Sherry, A. Kumar, G. Larosa, W. Newman,
K.J. Tracey, H. Yang, J. Exp. Med. 203 (2006) 1637–1642.
[55] J. Li, H. Wang, J.M. Mason, J. Levine, M. Yu, L. Ulloa, C.J. Czura, K.J. Tracey, H.
Yang, J. Immunol. Methods 289 (2004) 211–223.
[56] G. Chen, J. Li, X. Qiang, C.J. Czura, M. Ochani, K. Ochani, L. Ulloa, H. Yang, K.J.
Tracey, P. Wang, A.E. Sama, H. Wang, J. Lipid Res. 46 (2005) 623–627.
[57] D. Strassheim, J.S. Park, E. Abraham, Int. J. Biochem. Cell Biol. 34 (2002) 1527–
1533.
[58] A. Sodhi, S.K. Biswas, J. Interferon Cytokine Res. 22 (2002) 517–526.
[59] W. Arjumand, S. Sultana, Life Sci. 89 (2011) 422–429.
[60] J.M. Cherng, K.D. Tsai, Y.W. Yu, J.C. Lin, Radiat. Res. 176 (2011) 177–186.
[61] Y. Liu, J. Xiang, M. Liu, S. Wang, R.J. Lee, H. Ding, J. Pharm. Pharmacol. 63 (2011)
439–446.
[62] M. Takei, M. Kobayashi, D.N. Herndon, R.B. Pollard, F. Suzuki, Cytokine 35
(2006) 295–301.
[63] L. Mollica, F. De Marchis, A. Spitaleri, C. Dallacosta, D. Pennacchini, M. Zamai, A.
Agresti, L. Trisciuoglio, G. Musco, M.E. Bianchi, Chem. Biol. 14 (2007) 431–441.
J.N. Alves et al. / Archives of Biochemistry and Biophysics 537 (2013) 72–81 81[64] G. Sitia, M. Iannacone, S. Muller, M.E. Bianchi, L.G. Guidotti, J Leukoc Biol 81
(2007) 100–107.
[65] W. Wang, M. Luo, Y. Fu, S. Wang, T. Efferth, Y. Zu, Int. J. Nanomedicine 8 (2013)
1377–1383.
[66] S.N. Vogel, C.T. Hansen, D.L. Rosenstreich, J. Immunol. 122 (1979) 619–622.
[67] X. Wu, Y. Mi, H. Yang, A. Hu, Q. Zhang, C. Shang, Mol. Cell. Biochem. (2013) 12–
15.[68] T.T. Cornell, P. Rodenhouse, Q. Cai, L. Sun, T.P. Shanley, Infect Immun 78 (2010)
2868–2876.
[69] H. Fan, B. Zingarelli, V. Harris, G.E. Tempel, P.V. Halushka, J.A. Cook, Mol. Med.
14 (2008) 422–428.
[70] H. Li, Y. Wang, H. Zhang, B. Jia, D. Wang, D. Lu, R. Qi, Y. Yan, H. Wang, PLoS One
7 (2012) e52863.
